| News

Anaveon raises CHF 35 million

26.02.2019

Anaveon, an immuno-oncology biotech, has successfully concluded a Series A financing round led by Syncona, a UK Life Sciences fund, and joined by the Novartis Venture Fund. The company was founded with financing from BaseLaunch, the healthcare accelerator of BaselArea.swiss in December 2017 and in 2018 also raised additional seed money from the UZH Life Sciences Fund.

Anaveon is developing a selective interleukin-2 receptor (IL-2 receptor) agonist to fuel a patient’s immune system to respond to tumors. The naturally occurring IL-2 receptor stimulates a type of immune cell called a T-cell to attack tumors. Il-2 is already being used for the treatment of cancer. However, there are side effects and dose limiting toxicities associated with IL-2 therapy. Anaveon’s approach plans to overcome these challenges and the proceeds of the Series A financing  will now enable further development of its lead compound, as announced in a press release.

Anaveon was founded by Onur Boyman, Professor and Chair in the Department of Immunology at the University of Zurich (UZH), and Andreas Katopodis. Prior to this, Andreas Katopodis was Director of Autoimmunity, Transplantation and Inflammatory Disease at the Novartis Institutes for BioMedical Research.

Share this article

Sign up to receive our newsletter in your inbox.

You might also be interested in

Bottmedical enters the market with innovative braces
Basel Area Business & Innovation, Innovation, Invest

Bottmedical enters the market with innovative braces

The Basel-based startup Bottmedical has developed clear braces made from bio-based polymers. After closing a successful financing round, the company...

Read More
TargImmune raises nearly 18 million Swiss francs
Basel Area Business & Innovation, Innovation, Invest

TargImmune raises nearly 18 million Swiss francs

The Basel-based biotechnology firm TargImmune has raised 17.7 million Swiss francs as part of a financing round. It now intends...

Read More
KetoSwiss launches first product in the USA
Basel Area Business & Innovation, Innovation, Invest

KetoSwiss launches first product in the USA

The Basel-based biotech startup KetoSwiss develops innovative therapies for neurological disorders. Following a successful capital increase, the company now has...

Read More
For Swiss startups, China might be closer than it seems
Basel Area Business & Innovation, Invest

For Swiss startups, China might be closer than it seems

China wants to strengthen domestic demand and be less dependent on imports. This policy has huge implications for the life...

Read More
Basel Area treads unique path
Basel Area Business & Innovation, Innovation, Invest

Basel Area treads unique path

Basel Area is responsible for both location and innovation promotion. This approach, which is unique across Switzerland, is very successful...

Read More
Alentis secures 67 million US dollars
Basel Area Business & Innovation, Innovation, Invest

Alentis secures 67 million US dollars

The Basel-based biotechnology company Alentis Therapeutics has secured 67 million US dollars in a series B funding round. The funds...

Read More
RocketVax secures partners for coronavirus vaccine in Basel
Basel Area Business & Innovation, Innovation

RocketVax secures partners for coronavirus vaccine in Basel

RocketVax has found cooperation partners for the development of its innovative coronavirus vaccine. The University Hospital of Basel, the University...

Read More
Bright Peak secures investment of 107 million dollars
Basel Area Business & Innovation, Innovation, Invest

Bright Peak secures investment of 107 million dollars

Bright Peak has raised a total of 107 million US dollars as part of a financing round. The biotechnology firm...

Read More
LCB lands major contract
Basel Area Business & Innovation, Innovation, Invest

LCB lands major contract

LCB Sàrl is active in the areas of Human Machine Interface as well as software and electronics development. The company...

Read More
1 2 3 28

Do you have a question? We'd like to hear from you.